Cargando…

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

One way that tumors evade immune destruction is through tumor and stromal cell expression of arginine-degrading enzyme arginase-2 (ARG2). Here we describe the existence of pro-inflammatory effector T-cells that recognize ARG2 and can directly target tumor and tumor-infiltrating cells. Using a librar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weis-Banke, Stine Emilie, Hübbe, Mie Linder, Holmström, Morten Orebo, Jørgensen, Mia Aaboe, Bendtsen, Simone Kloch, Martinenaite, Evelina, Carretta, Marco, Svane, Inge Marie, Ødum, Niels, Pedersen, Ayako Wakatsuki, Met, Özcan, Madsen, Daniel Hargbøl, Andersen, Mads Hald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458644/ https://www.ncbi.nlm.nih.gov/pubmed/32923127 http://dx.doi.org/10.1080/2162402X.2020.1771142

Ejemplares similares

TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
por: Perez-Penco, Maria, et al.
Publicado: (2022)

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2022)

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment
por: Bendtsen, Simone Kloch, et al.
Publicado: (2022)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2021)

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2020)

Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade
por: Hübbe, Mie Linder, et al.
Publicado: (2020)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Novel immune modulatory vaccines targeting TGFβ
por: Andersen, Mads Hald
Publicado: (2023)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
por: Handlos Grauslund, Jacob, et al.
Publicado: (2021)

Immune Modulatory Properties of Collagen in Cancer
por: Rømer, Anne Mette Askehøj, et al.
Publicado: (2021)

Impact of peptide:HLA complex stability for the identification of SARS-CoV-2-specific CD8(+)T cells
por: Lie-Andersen, Olivia, et al.
Publicado: (2023)

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
por: Holmström, Morten O., et al.
Publicado: (2019)

CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment
por: Lecoq, Inés, et al.
Publicado: (2022)

First in man study: Bcl-Xl_42-CAF(®)09b vaccines in patients with locally advanced prostate cancer
por: Mørk, Sofie Kirial, et al.
Publicado: (2023)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot
por: Larsen, Stine Kiaer, et al.
Publicado: (2012)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
por: Hasselbalch, Hans Carl, et al.
Publicado: (2023)

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Arginase and pulmonary diseases
por: Maarsingh, Harm, et al.
Publicado: (2008)

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application
por: Junker, Niels, et al.
Publicado: (2011)

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

Natural CD4(+) T-Cell Responses against Indoleamine 2,3-Dioxygenase
por: Munir, Shamaila, et al.
Publicado: (2012)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
por: Hulen, Thomas Morgan, et al.
Publicado: (2023)

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2021)

Arginase and Arginine Dysregulation in Asthma
por: Benson, Renée C., et al.
Publicado: (2011)

Endothelial arginase II and atherosclerosis
por: Ryoo, Sungwoo, et al.
Publicado: (2011)

Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer
por: Gannon, Philippe O., et al.
Publicado: (2010)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

Therapeutic Cancer Vaccines in Combination with Conventional Therapy
por: Andersen, Mads Hald, et al.
Publicado: (2010)

Characterization of T-cell responses against IκBα in cancer patients
por: Munir, Shamaila, et al.
Publicado: (2012)

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes
por: Donia, Marco, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ihkga26lm06bo9kj5a19st7mnl